ACTIVE INGREDIENT: Bicalutamide
STRENGTH & PACK SIZE & GMS CODES:
50 mg Film-coated tablets x 28 ~ 88721
Combination therapy with Biluta 50 mg:
Treatment of advanced prostate cancer in combination with luteinizing hormone-releasing hormone (LHRH) analogue therapy or surgical castration.
Monotherapy with 3 tablets of Biluta 50 mg (150 mg bicalutamide):
Biluta at a dose of 150 mg is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression.